Long-awaited ISCHEMIA results to change practice, DAPA-HF elevates dapagliflozin for HFrEF
Description
ISCHEMIA trial hailed as practice changing
The largest-ever RCT of initial invasive versus conservative management of stable ischemic heart disease makes waves.
* * *
Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019
* * *
DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics
Further analyses from the DAPA-HF trial showed dapagliflozin cut death and heart failure events in HFrEF patients with no diabetes.
The TWILIGHT of aspirin post-PCI for ACS?
Patients do better post-PCI for non-ST-elevation ACS with ticagrelor monotherapy
Weaknesses exposed in valsartan recall
ED visits for hypertension in month after the 2018 recall spiked 55%
* * *
For more MDedge Podcasts, go to mdedge.com/podcasts
Email the show: podcasts@mdedge.com
Interact with us on Twitter: @MDedgeTweets
United States
